Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

Phio Pharmaceuticals (NASDAQ: PHIO) will host a live virtual fireside chat with Force Family Office on May 19, 2026 at 4 PM EDT, focused on innovations in skin cancer treatment and prevention.

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) will host a live virtual fireside chat with Force Family Office on May 19, 2026 at 4 PM EDT, focused on innovations in skin cancer treatment and prevention.

Recent highlights include Phase 1b data for PH-762 showing no dose-limiting toxicities or serious adverse events among 22 treated patients, a reported ~65% pathological response rate in cSCC (including 6 of 7 responders in the highest-dose cohort), targeted FDA engagement in Q2 2026, and cash projected to fund operations into the first half of 2027.

Positive

• PH-762 Phase 1b: 22 patients treated with no dose-limiting toxicities or serious adverse events
• Approximately 65% pathological response rate in cSCC across all PH-762 dosing cohorts
• Highest-dose PH-762 cohort showed 85% pathological response (6 of 7 cSCC patients)
• FDA engagement for next-stage PH-762 development targeted for Q2 2026
• Cash and cash equivalents projected to fund operations into first half of 2027

Negative

• None.

Argus May 12 session

+1.85% close to close Open Argus

Details

News Market Reaction – PHIO

On May 12, the day this news came out, PHIO closed 1.85% above the previous close.

Data tracked by StockTitan Argus for the May 12 session.

Market Context

This announcement highlights another investor-focused event to discuss Phio’s INTASYL platform and P...

Analysis

This announcement highlights another investor-focused event to discuss Phio’s INTASYL platform and PH-762, which has shown about 65% pathological response in cSCC overall and 85% in the highest dose cohort, with 22 patients treated. It reinforces plans for FDA engagement in Q2 2026 and a projected cash runway into H1 2027. Investors may track upcoming regulatory interactions, additional PH-762 data, and any use of the company’s financing programs as key milestones.

Key Figures

Patients treated: 22 patients Dose cohorts: 5 cohorts Pathological response rate: 65% +5 more

Patients treated

22 patients

PH-762 Phase 1b intratumoral trial across five dose-escalation cohorts

Dose cohorts

5 cohorts

PH-762 Phase 1b dose-escalation design

Pathological response rate

65%

cSCC pathological response across all PH-762 dosing cohorts

High-dose response rate

85% (6 of 7 patients)

cSCC pathological response in highest PH-762 dose cohort

FDA engagement timing

Q2 2026

Target for FDA discussions on next-stage PH-762 development

Cash runway

into H1 2027

Company projection for cash and cash equivalents coverage

Event date

May 19, 2026

Scheduled fireside chat with Force Family Office

Event time

4 PM EDT

Timing of May 19, 2026 virtual fireside chat

Historical Context

5 past events · Latest: May 07

5 events

1. May 07

   Earnings and update

   24h Move

   -6.1%

   Q1 2026 results with wider net loss and higher R&D plus ATM capacity.

2. Apr 23

   Investor roadshow

   24h Move

   -1.6%

   Virtual non-deal roadshow highlighting INTASYL platform and PH-762 data.

3. Apr 13

   Fireside chat

   24h Move

   +2.5%

   Force Family Office chat discussing INTASYL and PH-762 Phase 1b results.

4. Apr 09

   Conference presentation

   24h Move

   -3.9%

   Centri Capital Conference talk on PH-762 progress and immuno-oncology strategy.

5. Mar 30

   Manufacturing deal

   24h Move

   -4.8%

   U.S. cGMP manufacturing agreement to supply PH-762 for trials and potential launch.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

siRNA, gene silencing, intratumoral, cutaneous squamous cell carcinoma, +3 more

7 terms

siRNA medical

"clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

gene silencing medical

"INTASYL® gene silencing technology to eliminate cancer."

Gene silencing is a biological process that turns down or shuts off the activity of a specific gene so it stops making its product, like dimming or muting a single light in a room instead of cutting power to the whole house. Investors care because therapies or products that intentionally silence harmful genes can become new drugs, diagnostics, or royalties, affecting a company’s future revenue, risk profile, and valuation.

intratumoral medical

"PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous"

"Intratumoral" describes something that occurs or exists within a tumor, which is an abnormal growth of tissue. For investors, understanding intratumoral is important because it relates to medical treatments or research aimed at targeting the tumor directly, potentially leading to more effective therapies. Think of it as focusing treatment straight into the problem area, much like fixing a leak by working directly on the pipe itself.

cutaneous squamous cell carcinoma medical

"therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel"

A common form of skin cancer that starts in the thin, outer layer of the skin and can grow or, in some cases, spread to nearby tissue or organs. For investors, it matters because diagnosis rates, available treatments, and regulatory approvals shape demand for therapies, influence clinical trial results, and affect potential revenue for companies developing drugs, devices, or diagnostics — like spotting a stubborn weed that may require different tools to remove.

Merkel cell carcinoma medical

"melanoma and Merkel cell carcinoma. "We are excited to take part"

Merkel cell carcinoma is a rare, fast-growing form of skin cancer that starts in cells near the base of the skin and often spreads quickly to nearby tissues and organs. For investors, it matters because treatments for this aggressive disease can create high-value opportunities or risks: successful drugs or tests can unlock significant revenue and partnerships, while failed trials or regulatory setbacks can sharply affect a biotech company’s prospects — like a single critical test determining whether a new product succeeds or stalls.

pathological response medical

"reported a pathological response rate in cSCC across all dosing cohorts"

A pathological response is the change seen in tissue samples—often tumor tissue—after a medical treatment, as assessed under a microscope or by lab tests. Investors care because it provides direct evidence of whether a therapy is killing or shrinking diseased cells, acting like a close-up inspection of repairs after work is done; strong pathological responses can support regulatory approval, higher sales expectations, and a therapy’s perceived value.

immuno-oncology medical

"represents a differentiated and innovative approach to immuno-oncology."DATE: Tuesday"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attend

Featuring Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven Saltzstein

King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Steven Saltzstein, CEO, Force Family Office. Joining them will be Dr. Mary Spellman, Board Certified, licensed dermatologist who will explore both prevention and next-generation treatment strategies for various forms of skin cancer.

"We are excited to take part in this fireside chat with Force Family Office," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. "Dr. Spellman will discuss the future direction of dermatologic oncology and highlight how our INTASYL® siRNA program represents a differentiated and innovative approach to immuno-oncology."

DATE: Tuesday May 19, 2026

TIME: 4 PM EDT

REGISTRATION LINK: PHIO Pharma - Force Family Office

Recent Company Highlights

Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.

Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL^® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296886

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Phio Pharmaceuticals (NASDAQ: PHIO) discussing in the May 19, 2026 fireside chat?

Phio Pharmaceuticals will discuss innovations in skin cancer treatment and prevention in a virtual fireside chat. The event features dermatologist Dr. Mary Spellman, CEO Robert Bitterman, and Force Family Office CEO Steven Saltzstein, focusing on dermatologic oncology and Phio’s INTASYL siRNA immuno-oncology program.

When is the Phio Pharmaceuticals (PHIO) and Force Family Office virtual fireside chat?

The Phio Pharmaceuticals and Force Family Office fireside chat is scheduled for May 19, 2026 at 4 PM EDT. According to Phio, investors, advisors, and life sciences analysts are invited to register and attend the live virtual session on skin cancer treatment and prevention.

What are the latest PH-762 Phase 1b results reported by Phio Pharmaceuticals (PHIO)?

Phio reported PH-762 Phase 1b data in cSCC, melanoma, and Merkel cell carcinoma. According to Phio, 22 patients completed treatment with no dose-limiting toxicities or serious adverse events, and cSCC showed an approximate 65% pathological response rate across all cohorts, including 6 of 7 responders in the highest-dose group.

What pathological response rates did Phio (PHIO) report for PH-762 in cutaneous squamous cell carcinoma?

Phio reported an overall pathological response rate of about 65% in cSCC across all PH-762 dosing cohorts. According to Phio, the highest-dose cohort achieved an 85% pathological response, with 6 of 7 patients showing pathological responses to intratumoral PH-762 treatment.

How long is Phio Pharmaceuticals (PHIO) funded based on its current cash position?

Phio projects its cash and cash equivalents will fund operations into the first half of 2027. According to Phio, this projected runway supports ongoing development of PH-762 and planned regulatory engagement, including targeted FDA discussions on next-stage clinical development in the second quarter of 2026.

What regulatory plans has Phio Pharmaceuticals (PHIO) outlined for PH-762 after Phase 1b?

Phio is targeting FDA engagement regarding next-stage clinical development of PH-762 in the second quarter of 2026. According to Phio, this planned interaction follows Phase 1b intratumoral data in cSCC, melanoma, and Merkel cell carcinoma, including reported response rates and tolerability outcomes.